NCT01234025 2023-10-06Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)Ionis Pharmaceuticals, Inc.Phase 1/2 Completed113 enrolled
NCT01083615 2016-10-12A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)Achieve Life SciencesPhase 3 Terminated14 enrolled